CAR T-cell therapy consists of targeted immune system cell modification to attack the cells that produce the antibodies causing the…
en_news
Non-canonical proteins are unconventional protein products that are not part of the known protein-coding genome repertoire. They arise from unexpected…
Recently published in the Journal of Medical Genetics* results of a case-control study spearheaded by VHIO’s Judith Balmaña show that…
Intrahepatic cholangiocarcinoma (ICC) is a rare cancer with a poor prognosis. Surgery is the main curative option but up to…
Now published by the ESMO Daily Reporter (formerly by the ESMO Perspectives online magazine), the latest edition of On Target – Gathering…
Results of the phase II single arm, multi-site international CALYPSO study point to the efficacy of combining potent MET inhibitor…
A study led by researchers at the Hospital del Mar Medical Research Institute shows that the oxaliplatin administered in some…
Results of VHIO-led pharmacokinetic analysis of Omomyc, a therapeutic mini-protein that targets the MYC oncogene which is found deregulated in…
Recently published open access in the Journal for ImmunoTherapy of Cancer (1), findings from a study led by VHIO’s Alena…
The VHIO Radiomics Group participates in this new European project On January 1, 2023, a new EU-funded research project establishing…
